Patient receives first prescription for FDA-approved brain tumor treatment

December 5, 2011 By Sherri McGinnis González, University of Illinois at Chicago

(Medical Xpress) -- The University of Illinois Hospital is the first center in North America to prescribe a new FDA-approved treatment for patients with the most common and aggressive type of brain tumor, glioblastoma multiforme, or GBM.

The hospital is one of the first centers in the U.S. to receive training and certification to treat patients with recurrent GBM with a new therapy called Tumor Treating Fields. This novel, non-invasive therapy is provided using a portable device, the NovoTTF-100A System made by Novocure, which uses alternating to disrupt the rapid cell division exhibited by cancer cells.

David Messmer, 50, of Indiana is the first patient in the country to receive a prescription for the device outside of a clinical trial. He began treatment with the Novocure device Nov. 28 at the University of Illinois Hospital.

Messmer was diagnosed with GBM in November of last year. His tumor has continued to progress despite two , and radiation. With the support of his family, he says he was “willing to try anything."

"Chemo is just not working for me," Messmer said. "This is my next best hope."

GBM affects approximately 10,000 Americans each year. The median survival time from initial diagnosis is 15 months with optimal treatment, and median survival from the time of recurrence is only three to five months without additional effective treatment.

"Patients with recurrent GBM present a significant treatment challenge,” says Dr. Herbert Engelhard, chief of neuro-oncology at the University of Illinois Hospital, which was one of the primary clinical research sites for the approval trial. The clinical trial, Engelhard said, showed that patients treated with the NovoTTF had comparable median overall survival times, fewer side effects, and better quality-of-life scores compared to patients treated with chemotherapy.

"We are proud to work with Novocure to make this state-of-the-art therapy available to those GBM patients who need it," he said.

TTF therapy provides physicians with a fourth treatment option for cancer in addition to surgery, radiation therapy and chemotherapy. It has been shown to effectively inhibit tumor growth by inducing cell death. The NovoTTF is a portable, non-invasive medical device designed for continuous use throughout the day by the patient. The device is placed directly on the skin near the tumor. It creates an artificial, alternating electric field within the tumor, which disrupts cancer cell division and can cause complete destruction of the dividing . The most commonly reported side effect was a mild-to-moderate rash beneath the electrodes.

The U.S. Food and Drug Administration has approved the NovoTTF-100A System for use as a treatment for adult patients with recurrent GBM. The device is intended to be used alone as an alternative to standard medical therapy for GBM after surgical and options have been exhausted.

Explore further: Phase I trial begins using gene therapy and bone marrow stem cells in the treatment of brain cancer

Related Stories

Phase I trial begins using gene therapy and bone marrow stem cells in the treatment of brain cancer

November 14, 2011
University Hospitals (UH) Case Medical Center, Case Western Reserve University School of Medicine and Lentigen Corporation announced today the initiation of a novel Phase I clinical trial of LG631 gene therapy for the protection ...

Recommended for you

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma

January 17, 2018
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at ...

Dulling cancer therapy's double-edged sword

January 17, 2018
Researchers have discovered that killing cancer cells can actually have the unintended effect of fueling the proliferation of residual, living cancer cells, ultimately leading to aggressive tumor progression.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.